(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Blue Origin's next space tourism flight will break new ground for people with disabilities - 2Changing Negative Cash Mentalities: Enabling Your Monetary Excursion
- 3Step by step instructions to Protect Your Speculations with Cd Rates
- 4'Stranger Things' Season 5: When does Volume 2 come out? And Volume 3? Everything to know about the remaining episodes before the finale.
- 5Overseeing Individual budgets Successfully
- Uncover the Manageable Fish Practices: Sea agreeable Feasting
- Share your pick for the miniature headphones that you generally suggest!
- April's full moon decides the date of Easter — here's how it works
- Chemical leak in Oklahoma forces evacuations and leaves many ill
- A new mom skipped a routine appointment. An infected cut led to a devastating diagnosis
- Weather forecast, Turkana style: A goat's intestines tell it all
- These 45 exoplanets may be the best places to search for alien life
- Nitty gritty Manual for Picking Agreeable Tennis shoes
- Inn The executives: A Remunerating Profession Decision for Energetic People
